LMWX Injection is a specialized anticoagulant medication containing Enoxaparin Sodium, a low molecular weight heparin (LMWH) designed to prevent and treat thrombosis and embolism by selectively inhibiting Factor Xa and thrombin (Factor IIa). Offered in three precise dosage strengths—20mg/0.2mL, 40mg/0.4mL, and 60mg/0.6mL—delivered via ready-to-use prefilled syringes, LMWX facilitates ease of subcutaneous administration. It is especially indicated for prophylaxis of deep vein thrombosis (DVT) post-surgical procedures or prolonged immobilization, treatment of pulmonary embolism (PE), management of unstable angina and NSTEMI, and prevention of clotting during hemodialysis. LMWX Injection offers an improved safety profile compared to unfractionated heparin, minimizing bleeding risks and enhancing patient compliance through user-friendly dosing. This product is ideal for healthcare providers seeking an effective, reliable anticoagulant solution for at-risk patients requiring blood clot prevention or treatment. Supplied by Melizza Lifescience, an oncology pharmaceutical exporter based in India, LMWX Injection supports critical therapeutic needs in clinical and hospital settings.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Enoxaparin Sodium (Low Molecular Weight Heparin) |
| Available Dosage Strengths | 20mg/0.2mL, 40mg/0.4mL, 60mg/0.6mL |
| Administration Route | Subcutaneous injection via prefilled syringes |
| Mechanism of Action | Selective inhibition of Factor Xa and thrombin (Factor IIa) to prevent clot formation |
| Indications | Prophylaxis of DVT, treatment of PE, management of unstable angina and NSTEMI, hemodialysis anticoagulation |
| Packaging | Prefilled syringes for ready-to-use, accurate dosing |
| Safety Profile | Safer alternative to unfractionated heparin with reduced bleeding risk |
| Dosage Customization | Dose tailored to indication, patient weight, and risk factors |
| Attributes | Description |
|---|---|
| Generic Name | Enoxaparin Sodium |
| Therapeutic Category | Anticoagulant - Low Molecular Weight Heparin (LMWH) |
| Dosage Forms Available | Prefilled syringes for subcutaneous injection |
| Injection Volume per Syringe | 0.2mL, 0.4mL, 0.6mL depending on strength |
| Route of Administration | Subcutaneous (SC) |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
| Manufacturer | Melizza Lifescience, India |
| Indications Detailed | DVT prophylaxis post surgery/immobilization, PE treatment, unstable angina, NSTEMI, hemodialysis clot prevention |
| Contraindications | Not for intramuscular use; use only as directed under medical supervision |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
LMWX Injection is supplied in prefilled syringes of 20mg/0.2mL, 40mg/0.4mL, and 60mg/0.6mL strengths for subcutaneous administration.
No, LMWX Injection should only be administered subcutaneously and not intramuscularly to avoid risk of hematoma.
LMWX Injection is indicated for DVT prophylaxis post-surgery or immobilization, treatment of pulmonary embolism, prevention of clotting in unstable angina and NSTEMI patients, and anticoagulation during hemodialysis.
LMWX's targeted inhibition of Factor Xa and thrombin results in less bleeding risk and more predictable anticoagulant effects, offering improved safety over unfractionated heparin.
LMWX Injection should be stored in a cool and dry place away from direct light to maintain its stability and potency.
Country Of Origin: India
Product Name: LMWX Injection (Available in 20mg, 40mg, 60mg prefilled syringes)
Generic Name:
Product Description:
LMWX Injection contains Enoxaparin Sodium, a low molecular weight heparin with anticoagulant (blood-thinning) properties. It is widely used for the prevention and treatment of blood clots (thrombosis and embolism).
It works by inhibiting clotting factors Factor Xa and IIa (thrombin), preventing the formation of new clots and the growth of existing ones.
Available Strengths:
• LMWX 20mg/0.2mL Injection
• LMWX 40mg/0.4mL Injection
• LMWX 60mg/0.6mL Injection
(Supplied as prefilled syringes for subcutaneous administration.)
Indications:
• Prophylaxis of deep vein thrombosis (DVT), especially after surgery or in bedridden patients
• Treatment of pulmonary embolism (PE)
• Prevention of clotting in unstable angina and non-ST elevation myocardial infarction (NSTEMI)
• Used during hemodialysis to prevent clot formation in the extracorporeal circuit
Dosage & Administration:
• Administered subcutaneously (SC), usually in the abdominal area.
• Dose depends on indication, body weight, and patient’s risk profile.
• Should not be administered intramuscularly.
• To be used under strict medical supervision.
Key Benefits:
• Highly effective in preventing and treating blood clots.
• Ready-to-use prefilled syringes for convenient administration.
• Safer profile compared to unfractionated heparin.
BULK ONCOLOGY SUPPLIER FROM INDIA
ONCOLOGY PRODUCTS MELIZZA LIFESCIENCE
Melizza Lifescience
Exporter of Pharmaceutical Products
Inclusive of all taxes
You Save: 0
Rajkot , India
Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24gqfpm5460r1z4
